Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study

Abstract

Omalizumab is highly effective and safe in CIndU patients, with long estimated treatment duration mainly reflecting long disease duration. Our data show omalizumab's high potential as treatment in any subtype of CIndU and support its clinical use for these patients.